{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"54.82","value":"16.7"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"79.39","value":"33.3"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"8.33","value":"0"},{"groupId":"OG003","lowerLimit":"5.41","upperLimit":"57.09","value":"31.3"},{"groupId":"OG004","lowerLimit":"0.95","upperLimit":"52.38","value":"26.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"15"}],"units":"Participants"}],"title":"Safety Population"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"50.00","upperLimit":"100.00","value":"100"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"50.00","value":"0"},{"groupId":"OG003","lowerLimit":"75.00","upperLimit":"100.00","value":"100"},{"groupId":"OG004","lowerLimit":"34.94","upperLimit":"100.00","value":"80.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"t(11;14) Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"25.00","value":"0"},{"groupId":"OG001","lowerLimit":"50.00","upperLimit":"100.00","value":"100"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"25.00","value":"0"},{"groupId":"OG003","lowerLimit":"0.00","upperLimit":"47.35","value":"14.3"},{"groupId":"OG004","lowerLimit":"0.00","upperLimit":"77.30","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"title":"RAS Mutation Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"15"}],"units":"Participants"}],"description":"ORR was defined as a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) and was analyzed in the safety evaluable population and in the biomarker-selected sub-populations of t(11;14) and RAS mutations.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.","id":"OG000","title":"Safety Run-In: Cobimetinib + Venetoclax"},{"description":"Participants received cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.","id":"OG001","title":"Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab"},{"description":"Participants received the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants were allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG002","title":"A: Cobimetinib"},{"description":"Participants received cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG003","title":"B: Cobimetinib + Venetoclax"},{"description":"Participants received cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG004","title":"C: Cobimetinib + Venetoclax + Atezolizumab"}],"paramType":"NUMBER","populationDescription":"The safety evaluable population included all participants who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"From randomization to the first occurrence of a response as defined above (up to approximately 3 years, 7 months)","title":"Percentage of Participants With Overall Response Rate (ORR) as Determined by the Investigator Using International Myeloma Working Group (IMWG) Response Criteria","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}